Brentuximab vedotin (Adcetris®) accepted for use within NHS Scotland for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL)

Approval based on phase III study, in which brentuximab in combination with cyclophosphamide, doxorubicin and prednisone was associated with a significant improvement in progression-free survival vs. cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy.

Scottish Medicines Consortium